Aman Chauhan, MD
Hematology/Oncology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 16 years
- Graduated 2010
Offices
3 locations · UCSF Medical Group Business Services · University of California San Francisco · University of Miami
Hospitals listed: Univ of Miami Hospital and Clinics-Sylvester Compr. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chauhan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
State licence records
1 licence
- Florida ME160009Medical Doctor · since 2022 · expires 2027-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
2 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- Kasturba Medical College Manipal · MD2004–2010Medical school
Residency and fellowship
- University of Kentucky, Hematology and OncologyLEXINGTON, KY · 2015–2018
- Louisiana State University, Internal Medicine/PediatricsNEW ORLEANS, LA · 2011–2015
What else the board holds
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
Kentucky
Original Medicare doctor bills
$40,592
Medicare paid this office $40,592 for 122 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 77 | $21,956 | $125 |
| Return visit (30+ min) | 55 | $7,183 | $84 |
| New patient visit (60+ min) | 35 | $5,690 | $163 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 64 | $1,954 | $15 |
| Short return visit (20+ min) | 13 | $840 | $60 |
Who their Medicare patients are
122 Original Medicare patients in 2024. Average age 71 · Women 55% · Also on Medicaid 23% · Health risk score 3.12. Sicker patients than 9 in 10 peers; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 55% · Diabetes 39% · Coronary heart disease 30% · Chronic kidney disease 30% · Depression 28% · COPD 17% · Heart failure 16% · Atrial fibrillation 16% · Stroke 10%.
The office billed $147,492, Medicare allowed $52,053 and paid $40,592; for 468 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 122 | 468 | 71 | 3.12 | $147,492 | $40,592 |
| 2023 | 73 | 193 | 69 | 2.84 | $85,308 | $22,807 |
| 2022 | 67 | 125 | 69 | 2.29 | $37,665 | $12,793 |
| 2021 | 94 | 223 | 70 | 2.82 | $65,860 | $21,948 |
| 2020 | 96 | 254 | 70 | 2.60 | $73,536 | $21,080 |
| 2019 | 100 | 220 | 68 | 2.36 | $57,499 | $16,317 |
| 2018 | 24 | 48 | 68 | 1.61 | $14,320 | $4,211 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 39 | $12,691 | $122 |
| New patient visit (60+ min) | 25 | $3,992 | $160 |
| Return visit (30+ min) | 23 | $2,961 | $82 |
2022: 3 services
| Long return visit (40+ min) | 26 | $6,137 | $114 |
| Return visit (30+ min) | 20 | $2,045 | $73 |
| New patient visit (60+ min) | 11 | $1,532 | $139 |
2021: 5 services
| Long return visit (40+ min) | 38 | $10,973 | $110 |
| Return visit (30+ min) | 32 | $3,431 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,465 | $154 |
| New patient visit (60+ min) | 14 | $1,919 | $137 |
| Short return visit (20+ min) | 11 | $785 | $49 |
2020: 5 services
| Long return visit (40+ min) | 31 | $8,539 | $82 |
| Return visit (30+ min) | 31 | $3,419 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,352 | $160 |
| New patient visit (45+ min) | 12 | $1,223 | $102 |
| Short return visit (20+ min) | 13 | $566 | $38 |
2019: 5 services
| Return visit (30+ min) | 29 | $4,208 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,029 | $104 |
| Long return visit (40+ min) | 15 | $2,626 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,698 | $154 |
| Short return visit (20+ min) | 14 | $701 | $39 |
Medicaid work
$5,848 in 2021
Medicaid paid $5,848 for 141 billed services this clinician did in 2021, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 141 | $5,848 |
| 2021 | 141 | 1 | 14 | $5,848 |
| 2020 | 78 | 1 | 14 | $3,165 |
See the largest Medicaid services in earlier years
2020
| Long return visit (40+ min) | 78 | $3,165 |
Drugs they prescribed that Part D paid
$229,844
Pharmacies billed $229,844 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (13 of 161) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%.
135 generic and 26 brand-name prescriptions · $229,844 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Everolimus | 26 | $41,056 | $1,579 |
| Prochlorperazine Maleate | 16 | $303 | $19 |
| Dexamethasone | 17 | $138 | $8 |
| Methylprednisolone | 18 | $102 | $6 |
Year by year
| 2024 | 161 | 51 | 8% (13) | 16% | $229,844 |
| 2023 | 164 | 33 | 10% (16) | 15% | $298,449 |
| 2022 | 307 | 33 | 11% (35) | 30% | $380,675 |
| 2021 | 356 | 45 | 21% (73) | None | $385,954 |
| 2020 | 498 | 50 | 26% (131) | None | $191,532 |
| 2019 | 178 | 28 | 21% (37) | None | $93,046 |
| 2018 | 21 | None | None | None | $528 |
| 2017 | 43 | 18 | None | None | $8,942 |
| 2016 | 11 | None | 0% (0) | 0% | $667 |
| 2015 | 39 | 15 | None | None | $1,134 |
| 2014 | 14 | None | 0% (0) | None | $382 |
| 2013 | 13 | None | 0% (0) | None | $1,424 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Everolimus | 16 | $174,408 | $10,900 |
| Xermelo | 12 | $109,843 | $9,154 |
| Prochlorperazine Maleate | 30 | $629 | $21 |
| Ondansetron Odt | 21 | $521 | $25 |
2022: 13 drugs
| Xermelo | 22 | $176,436 | $8,020 |
| Afinitor | 12 | $163,564 | $13,630 |
| Eliquis | 19 | $13,082 | $689 |
| Xarelto | 16 | $10,227 | $639 |
| Dronabinol | 11 | $2,668 | $243 |
| Ondansetron | 29 | $759 | $26 |
| Oxycodone | 17 | $609 | $36 |
| Prochlorperazine Maleate | 31 | $412 | $13 |
| Olanzapine | 12 | $170 | $14 |
| Dexamethasone | 11 | $143 | $13 |
| Sertraline | 11 | $128 | $12 |
| Prednisone | 14 | $45 | $3 |
| Lorazepam | 12 | $13 | $1 |
2021: 8 drugs
| Xermelo | 26 | $190,499 | $7,327 |
| Oxycodone | 43 | $1,228 | $29 |
| Ondansetron | 31 | $1,057 | $34 |
| Prochlorperazine Maleate | 34 | $1,018 | $30 |
| Morphine Sulfate Er | 24 | $1,011 | $42 |
| Dexamethasone | 20 | $378 | $19 |
| Mirtazapine | 15 | $129 | $9 |
| Pantoprazole | 13 | $63 | $5 |
2020: 10 drugs
| Ondansetron | 56 | $4,380 | $78 |
| Dronabinol | 23 | $3,332 | $145 |
| Oxycodone | 90 | $2,497 | $28 |
| Prochlorperazine Maleate | 46 | $1,728 | $38 |
| Morphine Sulfate Er | 34 | $1,182 | $35 |
| Dexamethasone | 36 | $521 | $14 |
| Alprazolam | 15 | $167 | $11 |
| Levothyroxine | 11 | $134 | $12 |
| Promethazine | 11 | $128 | $12 |
| Mirtazapine | 17 | $106 | $6 |
2019: 5 drugs
| Oxycodone | 24 | $841 | $35 |
| Ondansetron | 21 | $591 | $28 |
| Dexamethasone | 17 | $514 | $30 |
| Prochlorperazine Maleate | 17 | $438 | $26 |
| Mirtazapine | 11 | $143 | $13 |
Money from drug and device companies
$33,351 in 2025
| 2025 | 6 | 40 | $27,769 | $33,351 |
| 2024 | 6 | 32 | $19,690 | $24,934 |
| 2023 | 4 | 5 | $14,468 | $14,489 |
| 2022 | 3 | 3 | $4,090 | $4,215 |
| 2021 | 3 | 8 | $10,508 | $10,713 |
| 2020 | 2 | 9 | $7,850 | $9,124 |
| 2019 | 3 | 7 | $1,820 | $2,619 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Exelixis | Cabometyx | $13,128 | 24 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $12,021 | 5 payments
|
| Genzyme | None | $4,143 | 3 payments
|
| TerSera Therapeutics | Xermelo | $3,541 | 3 payments
|
| Novartis Pharmaceuticals | None | $312 | 2 payments
|
| Curium US | Detectnet | $206 | 3 payments
|
See all 40 published payments
| Exelixis | Paid to speak or teach · 2025-12-18 | Cabometyx | $300 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-12-08 | None | $6,598 |
| Exelixis | Paid to speak or teach · 2025-11-13 | Cabometyx | $900 |
| Exelixis | Travel · 2025-11-01 | Cabometyx | $187 |
| Exelixis | Meals · 2025-11-01 | Cabometyx | $67 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-25 | None | $59 |
| Exelixis | Meals · 2025-10-23 | None | $175 |
| TerSera Therapeutics | Consulting · 2025-10-22 | Xermelo | $3,430 |
| TerSera Therapeutics | Meals · 2025-10-22 | Xermelo | $50 |
| TerSera Therapeutics | Meals · 2025-10-22 | Xermelo | $61 |
| Exelixis | Meals · 2025-10-18 | Cabometyx | $172 |
| Exelixis | Consulting · 2025-10-09 | Cabometyx | $3,300 |
| Exelixis | Travel · 2025-10-06 | Cabometyx | $190 |
| Exelixis | Travel · 2025-10-03 | Cabometyx | $354 |
| Exelixis | Travel · 2025-10-03 | Cabometyx | $824 |
| Exelixis | Travel · 2025-10-03 | Cabometyx | $190 |
| Exelixis | Travel · 2025-10-01 | Cabometyx | $6 |
| Exelixis | Travel · 2025-09-30 | Cabometyx | $70 |
| Exelixis | Travel · 2025-09-30 | Cabometyx | $573 |
| Exelixis | Travel · 2025-09-30 | Cabometyx | $70 |
| Exelixis | Travel · 2025-09-30 | Cabometyx | $47 |
| Exelixis | Travel · 2025-09-30 | Cabometyx | $36 |
| Exelixis | Meals · 2025-09-20 | Cabometyx | $137 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-08-19 | None | $1,480 |
| Exelixis | Paid to speak or teach · 2025-07-25 | Cabometyx | $900 |
| Exelixis | Honoraria · 2025-07-23 | Cabometyx | $2,400 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-05-30 | None | $925 |
| Exelixis | Meals · 2025-05-29 | Cabometyx | $144 |
| Exelixis | Travel · 2025-05-28 | Cabometyx | $352 |
| Exelixis | Travel · 2025-05-28 | Cabometyx | $834 |
| Exelixis | Paid to speak or teach · 2025-03-28 | Cabometyx | $900 |
| Curium US | Meals · 2025-03-02 | Detectnet | $37 |
| Curium US | Meals · 2025-03-02 | Detectnet | $78 |
| Novartis Pharmaceuticals | Meals · 2025-03-01 | None | $274 |
| Novartis Pharmaceuticals | Travel · 2025-03-01 | None | $37 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-02-18 | Spevigo | $2,960 |
| Curium US | Meals · 2025-02-11 | Detectnet | $92 |
| Genzyme | Consulting · 2025-01-22 | None | $3,677 |
| Genzyme | Travel · 2025-01-22 | None | $352 |
| Genzyme | Meals · 2025-01-22 | None | $115 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $24,934
| Exelixis | Cabometyx | $15,634 | 18 payments
|
| Curium US | None | $5,093 | 7 payments
|
| Lantheus Medical Imaging | None | $2,880 | 2 payments
|
| TerSera Therapeutics | Xermelo | $1,005 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $224 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $98 | 1 payment
|
2023: $14,489
| Curium US | Detectnet | $6,600 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $4,388 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $3,480 | 1 payment
|
| Cardinal Health 414 | None | $22 | 1 payment
|
2022: $4,215
| Advanced Accelerator Applications | Lutathera | $2,500 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $1,590 | 1 payment
|
| Novartis Pharmaceuticals | Lutathera | $125 | 1 payment
|
2021: $10,713
| TerSera Therapeutics | Xermelo | $7,020 | 3 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $3,604 | 3 payments
|
| Novartis Pharmaceuticals | Lutathera | $89 | 2 payments
|
2020: $9,124
| Lexicon Pharmaceuticals | Xermelo | $7,574 | 8 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $1,550 | 1 payment
|
2019: $2,619
| Ipsen Biopharmaceuticals | Somatuline Depot | $2,122 | 4 payments
|
| Ipsen Innovation | Somatuline Depot | $474 | 2 payments
|
| Exelixis | None | $22 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-9: A Phase Ib Open-Label Dose Escalation and Dose Confirmation Safety Study of Intravenous Bi 764532 in Combination With A Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-Based Chemotherapy · 2025 | Their institution | $1,207,047 |
| Alkermes, Inc. · A Study of the Effects of Alks 4230 on Subjects With Solid Tumors · 2020 | Their institution | $763,784 |
| Novartis Pharmaceuticals Corporation · Net Retreat: A Phase II Rct of Lu-177 Dotatate Retreatment Vs. Everolimus in Metastatic/Unresectable Small Bowel Net · 2025 | Their institution | $726,648 |
| Novartis Pharmaceuticals Corporation · Net Retreat: A Phase II Rct of Lu-177 Dotatate Retreatment Vs. Everolimus in Metastatic/Unresectable Small Bowel Net · 2024 | Their institution | $438,400 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial To Investigate Safety and Tolerability of Bi 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patients With Neuroendocrine Carcinomas (Nec) · 2025 | Their institution | $415,685 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Study in Sclc and Epnec · 2024 | Their institution | $412,272 |
| Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2021 | Their institution | $284,900 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phi in 2l Sclc With Combination of Bi 764532 + Topotecan · 2024 | Their institution | $254,648 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025 | Their institution | $134,240 |
| Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2022 | Their institution | $68,000 |
| TerSera Therapeutics LLC · Telotristate With Lutathera in Nets · 2020 | Their institution | $50,484 |
| Amgen Inc. · Tarlatamab 20200439 · 2023 | Their institution | $41,817 |
| Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2020 | Their institution | $34,000 |
| Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2019 | Their institution | $25,000 |
| E.R. Squibb & Sons, L.L.C. · Phase 1b/3 Global, Randomized, Controlled, Open-Label Trial Comparing Treatment With Ryz101 To Standard of Care Therapy in Subjects With Inoperable, Advanced, Sstr+, Well-Differentiated Gep-Nets That Have Progressed Following Prior 177lu-Ssa Therapy · 2024 | Their institution | $23,944 |
| Novartis Pharmaceuticals Corporation · Lumiere: A Phase 1/2, Multicenter, Open-Label, Non-Randomized Study To Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177lu-Fap-2286 in Patients With An Advanced Solid Tumor · 2025 | Their institution | $23,654 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phi in Dll3+ 1l Epnec With Bi 764532 + Chemo · 2024 | Their institution | $22,914 |
| E.R. Squibb & Sons, L.L.C. · Phase 1b Single Arm, Open-Label Trial of Ryz101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor · 2024 | Their institution | $22,439 |
| E.R. Squibb & Sons, L.L.C. · Phase II Study of Combination Nivolumab With Rucaparib in Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet. · 2023 | Their institution | $20,981 |
| Y-mAbs Therapeutics, Inc. · Phase 1 Trial With Gd2-Sada:177lu-Dota Drug Complex in Patients With Recurrent Or Refractory Metastatic Solid Tumors Known To Express Gd2, Including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma · 2024 | Their institution | $19,670 |
| Novartis Pharmaceuticals Corporation · A Phase Ib Dose Finding Study Assessing Safety and Activity of [177lu]Lu-Dota-Tate in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte · 2022 | Their institution | $14,154 |
| E.R. Squibb & Sons, L.L.C. · Phase II Study of Combination Nivolumab With Rucaparib in Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet. · 2024 | Their institution | $10,508 |
| Novartis Pharmaceuticals Corporation · Research Publication/Writing Support · 2025 | This clinician | $7,435 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022 | This clinician | $6,324 |
| Amgen Inc. · Tarlatamab 20200439 · 2021 | Their institution | $6,200 |
| Amgen Inc. · Tarlatamab 20200439 · 2022 | Their institution | $5,856 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Phase II Study in Sclc and Epnec · 2024 | Their institution | $4,349 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial To Investigate Safety and Tolerability of Bi 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patients With Neuroendocrine Carcinomas (Nec) · 2025 | Their institution | $3,683 |
| TerSera Therapeutics LLC · Randomized, Parallel Arm, Phase II Study of Telotristat (Xermelo) in Combination With Lutetium Lu 177 Dotatate (Lutathera) in Well Differentiated Neuroendocrine Tumors (Nets) · 2022 | Their institution | $3,558 |
| Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2022 | Their institution | $2,941 |
| Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2023 | Their institution | $2,694 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-9: A Phase Ib Open-Label Dose Escalation and Dose Confirmation Safety Study of Intravenous Bi 764532 in Combination With A Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-Based Chemotherapy · 2025 | Their institution | $2,622 |
| Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025 | This clinician | $2,442 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Phi in 2l Sclc With Combination of Bi 764532 + Topotecan · 2024 | Their institution | $1,622 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025 | Their institution | $1,484 |
| Boehringer Ingelheim International GmbH · Phase II Study in Sclc and Epnec · 2024 | Their institution | $785 |
| Boehringer Ingelheim International GmbH · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025 | Their institution | $640 |
| Novartis Pharmaceuticals Corporation · A Multicenter Open-Label Study To Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (Gep-Net) Tumors, Pheochromocytoma and Paragangliomas · 2023 | Their institution | $421 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Phi in Dll3+ 1l Epnec With Bi 764532 + Chemo · 2024 | Their institution | $370 |
| Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177lu]Lu-Ff58 in Patients With Selected Advanced Solid Tumors · 2024 | Their institution | $284 |
| Novartis Pharmaceuticals Corporation · A Phase Ib Dose Finding Study Assessing Safety and Activity of [177lu]Lu-Dota-Tate in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte · 2025 | Their institution | $158 |
| Novartis Pharmaceuticals Corporation · A Phase III Multi-Center, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced Gep-Net · 2023 | Their institution | $140 |
| Novartis Pharmaceuticals Corporation · A Multicenter Open-Label Study To Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (Gep-Net) Tumors, Pheochromocytoma and Paragangliomas · 2024 | Their institution | $102 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1902193147
- Licence
- FL ME160009Florida ME160009: Active
- Group
- UCSF Medical Group Business Services · University of California San Francisco · University of Miami
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1120 Nw 14th St Fl 6, Miami, FL, 33136
- NPI first listed
- 2011-07-08
- NPI last updated
- 2025-12-04
- NPI record certified
- 2025-12-04
This is when the NPI record was last certified, not a medical board exam.